Ardelyx Inc. (ARDX)
Ardelyx: Strong IBSRELA Growth, But Heavy Operational Spend Clouds Profitability
Ardelyx, Inc. delivered strong FY 2025 revenue growth, driven by Ibsrela, but missed on earnings due to sharply higher SG&A and R&D costs. Ibsrela's accelerating momentum underpins management's guidance for $410–$430M 2026 revenue and a $1B annual target by 2029, supported by patent protection through 2042. Xphozah revenue is declining and maturing, while heavy operational spend and net losses raise concerns about cost discipline and sustainability.
Ardelyx, Inc. (ARDX) Q4 2025 Earnings Call Transcript
Ardelyx, Inc. (ARDX) Q4 2025 Earnings Call Transcript
Ardelyx (ARDX) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Ardelyx (ARDX) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Ardelyx (ARDX) Reports Break-Even Earnings for Q4
Ardelyx (ARDX) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of $0.02. This compares to earnings of $0.02 per share a year ago.
Ardelyx (ARDX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
Ardelyx (ARDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
All You Need to Know About Ardelyx (ARDX) Rating Upgrade to Buy
Ardelyx (ARDX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Ardelyx: Assessment Of Acquisition Rumors
Ardelyx: Assessment Of Acquisition Rumors
Strength Seen in Ardelyx (ARDX): Can Its 15.0% Jump Turn into More Strength?
Ardelyx (ARDX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Ardelyx: IBSRELA Momentum Drives Opportunity
Ardelyx has transformed into a commercial powerhouse with two FDA-approved, first-in-class drugs, IBSRELA and XPHOZAH, driving robust revenue growth. IBSRELA's rapid uptake and projected $410–$430 million 2026 revenue, alongside a patent extension to 2041, create a durable, generational asset and significant terminal value. XPHOZAH's $100M+ annual revenue confirms unmet need in hyperphosphatemia, but its slower growth and reimbursement complexity present ongoing risk to the renal franchise.
Are Medical Stocks Lagging Ardelyx (ARDX) This Year?
Here is how Ardelyx (ARDX) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.
Wall Street Analysts See a 92.12% Upside in Ardelyx (ARDX): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 92.1% in Ardelyx (ARDX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Ardelyx (ARDX) Moves 5.5% Higher: Will This Strength Last?
Ardelyx (ARDX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
